EGFR and cancer: A meta-analysis of toxicity data pooled from 28 randomized controlled trials, which investigated EGFR TKIs in patients with various cancers, reported diarrhea, rash, mucositis, alanine aminotransferase increased, and skin reaction as most common any grade adverse events, while the most frequently reported grade ≥3 toxicities included mucositis, pain, metabolism and nutrition disorders, diarrhea, dyspnea, and hypertension (172).